12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ARX-04: Phase II started

AcelRx began a double-blind, placebo-controlled, dose-finding, U.S. Phase II trial to evaluate 20 and 30 µg sublingual ARX-04 given hourly as needed for 12 hours in about 100 patients following...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >